BackBellicum Pharmaceuticals Overview

Bellicum Pharmaceuticals Common Stock

Track Bellicum Pharmaceuticals's common stock ($98K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Common Stock
$98000.00
12.64% YoYΔ $11000.00 vs prior year quarter

Peer average

Loading

Bellicum Pharmaceuticals Common Stock History

Loading

Bellicum Pharmaceuticals vs. peers: Common Stock Comparison

Loading

Bellicum Pharmaceuticals Common Stock Growth (YoY per quarter)

Latest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.

Loading

Bellicum Pharmaceuticals (BLCM) FAQ

Bellicum Pharmaceuticals posts a common stock of $98K as of September 2023. That compares with $87K in the prior-year period — up 12.6% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Bellicum Pharmaceuticals's common stock was $87K. The latest reading is $98K — a 12.6% year-over-year increase (period ending September 2023). Use the history and growth charts on this page for a longer lookback.

Common Stock is one piece of Bellicum Pharmaceuticals's financial statement story. At $98K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for BLCM's common stock usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Bellicum Pharmaceuticals's other metric pages and overview cover the third.

Judging Bellicum Pharmaceuticals against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in common stock easier to interpret. Start with $98K here, then scan peer and history charts to see if the gap is persistent.